RxDoctor Payments Data

Ashley Daniel, NP

Nurse Practitioner · Germantown, TNNPI 1306417548

Payments from drug & device makers

$5,457in general payments, 2019–2025

Across 183 payments — averaging $29.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$954
  • Novartis$613
  • Merck$597
  • Novo Nordisk$572
  • Boehringer Ingelheim$314
  • E.r. Squibb & Sons, L.L.C.$273
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$5,457100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,457 in reported general payments places this provider in the 90th percentile of 2,662 nurse practitioner providers in Tennessee.

See all nurse practitioner providers in Tennessee

Medicare billing

Part B allowed, 2024
$4,226
Medicare patients
33
Services billed
67

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban55$69,141
XareltoRivaroxaban19$24,715
EntrestoSacubitril/Valsartan22$22,509
JardianceEmpagliflozin16$17,411
Metoprolol Succinate57$923
Potassium Chloride25$850
Ezetimibe17$807
Rosuvastatin Calcium40$725
Flecainide Acetate13$519
Atorvastatin Calcium45$491
Carvedilol29$313
Losartan Potassium27$302
Furosemide39$278
Amlodipine Besylate50$276
Lisinopril24$226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$161$69,14155 claims
Johnson & JohnsonXarelto$177$24,71519 claims
NovartisEntresto$613$22,50922 claims
Boehringer IngelheimJardiance$314$17,41116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,662 nurse practitioner providers in Tennessee.

Other nurse practitioner in Germantown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →